204 related articles for article (PubMed ID: 23663906)
1. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
2. Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.
Brinkhuis F; Goettsch WG; Mantel-Teeuwisse AK; Bloem LT
BMJ; 2024 Feb; 384():e077391. PubMed ID: 38418086
[TBL] [Abstract][Full Text] [Related]
3. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
Eur J Health Econ; 2023 Nov; ():. PubMed ID: 37962724
[TBL] [Abstract][Full Text] [Related]
4. Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer.
Vassal G; Kearns P; Blanc P; Scobie N; Heenen D; Pearson A
Eur J Cancer; 2017 Oct; 84():149-158. PubMed ID: 28818704
[TBL] [Abstract][Full Text] [Related]
5. Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.
Liberti L; Stolk P; McAuslane JN; Schellens J; Breckenridge AM; Leufkens H
Oncologist; 2015 Jun; 20(6):683-91. PubMed ID: 25948678
[TBL] [Abstract][Full Text] [Related]
6. Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019.
Badia X; Vico T; Shepherd J; Gil A; Poveda-Andrés JL; Hernández C
Orphanet J Rare Dis; 2020 Aug; 15(1):224. PubMed ID: 32859228
[TBL] [Abstract][Full Text] [Related]
7. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
Permanand G; Mossialos E; McKee M
Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
[TBL] [Abstract][Full Text] [Related]
8. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
Vassal G; de Rojas T; Pearson ADJ
Lancet Child Adolesc Health; 2023 Mar; 7(3):214-222. PubMed ID: 36682367
[TBL] [Abstract][Full Text] [Related]
9. Oncologic orphan drugs approved in the EU - do clinical trial data correspond with real-world effectiveness?
Schuller Y; Biegstraaten M; Hollak CEM; Klümpen HJ; Gispen-de Wied CC; Stoyanova-Beninska V
Orphanet J Rare Dis; 2018 Nov; 13(1):214. PubMed ID: 30486835
[TBL] [Abstract][Full Text] [Related]
10. Use of biomarkers in the context of orphan medicines designation in the European Union.
Tsigkos S; Llinares J; Mariz S; Aarum S; Fregonese L; Dembowska-Baginska B; Elbers R; Evers P; Foltanova T; Lhoir A; Corrêa-Nunes A; O'Connor D; Voordouw A; Westermark K; Sepodes B
Orphanet J Rare Dis; 2014 Jan; 9():13. PubMed ID: 24461084
[TBL] [Abstract][Full Text] [Related]
11. Trends in orphan medicinal products approvals in the European Union between 2010-2022.
Bouwman L; Sepodes B; Leufkens H; Torre C
Orphanet J Rare Dis; 2024 Feb; 19(1):91. PubMed ID: 38413985
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, safety and costs of orphan drugs: an evidence-based review.
Onakpoya IJ; Spencer EA; Thompson MJ; Heneghan CJ
BMJ Open; 2015 Jun; 5(6):e007199. PubMed ID: 26109112
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022.
Wu J; Yang Y; Yu J; Qiao L; Zuo W; Zhang B
Orphanet J Rare Dis; 2023 Nov; 18(1):368. PubMed ID: 38017575
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.
Jokura Y; Yano K; Yamato M
J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195
[TBL] [Abstract][Full Text] [Related]
15. Belgian observational survival data (incidence years 2004-2017) and expenditure for innovative oncology drugs in twelve cancer indications.
Neyt M; Devos C; Thiry N; Silversmit G; De Gendt C; Van Damme N; Castanares-Zapatero D; Hulstaert F; Verleye L
Eur J Cancer; 2023 Mar; 182():23-37. PubMed ID: 36731327
[TBL] [Abstract][Full Text] [Related]
16. Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation.
Kalland ME; Pose-Boirazian T; Palomo GM; Naumann-Winter F; Costa E; Matusevicius D; Duarte DM; Malikova E; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
Gene Ther; 2024 Mar; ():. PubMed ID: 38480914
[TBL] [Abstract][Full Text] [Related]
17. Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.
Zosso-Pavic M; Li Q; Atiek E; Wolfer A; Rohr UP
Lancet Oncol; 2024 Jun; 25(6):770-778. PubMed ID: 38754450
[TBL] [Abstract][Full Text] [Related]
18. Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases.
Staab T; Isbary G; Amelung VE; Ruof J
BMC Health Serv Res; 2016 Nov; 16(1):651. PubMed ID: 27842592
[TBL] [Abstract][Full Text] [Related]
19. The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products.
Palomo GM; Pose-Boirazian T; Naumann-Winter F; Costa E; Duarte DM; Kalland ME; Malikova E; Matusevicius D; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
Mol Ther; 2023 Dec; 31(12):3414-3423. PubMed ID: 37794679
[TBL] [Abstract][Full Text] [Related]
20. Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries.
Gluud C; Kubiak C; Whitfield K; Byrne J; Huemer KH; Thirstrup S; Libersa C; Barraud B; Grählert X; Dreier G; Geismann S; Kuchinke W; Temesvari Z; Blasko G; Kardos G; O'Brien T; Cooney M; Gaynor S; Schieppati A; de Andres F; Sanz N; Kreis G; Asker-Hagelberg C; Johansson H; Bourne S; Asghar A; Husson JM; Demotes-Mainard J
Trials; 2012 Mar; 13():27. PubMed ID: 22452964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
